Abstract:Purpose. Human pregnane X receptor (hPXR) has a key role in regulating metabolism of endogenous and exogenous substances. Identification of novel hPXR activators among commercial drugs aids in avoiding drug-drug interactions with future co-administered drugs. Methods. Virtual screening with Structure-Activity Relationship (SAR) models has been applied for identification of novel hPXR activators. Ligand-based modeling was conducted with Discover Studio (DS) 2.1. Bayesian classification models were generated with a training set comprising 177 compound, and were validated with a test set with 145 compounds. The activities of commonly prescribed drugs from SCUT database were predicted with one of the Bayesian models. Cell-based luciferase reporter assay was used for evaluation of chemical-mediated hPXR activation. HepG2 cells were co-transfected with PXR expression vector and CYP2B6-luciferase reporter construct. 0.1% DMSO solution was used as vehicle control while rifampicin as the positive control. The binding mode between an experimental validated hPXR modulators and hPXR were studied by docking a ligand into hPXR binding domain (PDB ID: 1NRL) with programs FlexX and SurFlex. Results. The Bayesian models showed specificity and overall prediction accuracy up to 0.92 and 0.69 for test set compounds. One Bayesian model with specificity of 0.92 was selected to screen the SCUT database and retrieved 113 hits. 17 compounds were chosen for in vitro testing. The luciferase reporter assay confirmed that seven drugs, i.e., fluticasone, nimodipine, nisoldipine, beclomethasone, finasteride, flunisolide, and megestrol were previously unidentified potent or moderate hPXR activators, with 2.7 to 18.5- fold increase in luciferase activity compared to vehicle control. Conclusion. In this study, virtual screening based on SAR models successfully identified seven novel hPXR activators among FDA approved and commonly prescribed drugs. The same approach could be used for identification of activators or inhibitors of other protein targets.

In silico prediction of pregnane X receptor activators by machine learning approaches.

In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches

Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique.

Predicting the Androgenicity of Structurally Diverse Compounds from Molecular Structure Using Different Classifiers

Machine Learning Based Models for High-Throughput Classification of Human Pregnane X Receptor Activators

Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs Via Ligand-Based Virtual Screening

Identification of Hpxr Modulators Via Sar-Based Virtual Screening

Predictive Models for Identifying the Binding Activity of Structurally Diverse Chemicals to Human Pregnane X Receptor.

Predicting selective liver X receptor β agonists using multiple machine learning methods.

Prediction of Farnesoid X Receptor Disruptors with Machine Learning Methods.

Prediction of bioactivities of microsomal prostaglandin E2 synthase-1 inhibitors by machine learning algorithms

Initial Development of Automated Machine Learning-Assisted Prediction Tools for Aryl Hydrocarbon Receptor Activators

Prediction of cytochrome P450-mediated bioactivation using machine learning models and in vitro validation

LASSO-ing Potential Nuclear Receptor Agonists and Antagonists: A New Computational Method for Database Screening

Prediction of Estrogen Receptor Agonists and Characterization of Associated Molecular Descriptors by Statistical Learning Methods.

Identification of novel pregnane X receptor activators from traditional Chinese medicines

In Silico Predication of Nuclear Hormone Receptors for Organic Pollutants by Homology Modeling and Molecular Docking

Identifying farnesoid X receptor agonists by naïve Bayesian and recursive partitioning approaches

Machine learning approaches for predicting compounds that interact with therapeutic and ADMET related proteins.

Prediction of HIV‐1 Protease Inhibitors Using Machine Learning Approaches

Machine learning prediction of dioxin lipophilicity and key feature Identification